{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:09:55Z","timestamp":1788887395889,"version":"build-2803163510"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>To assess the impact of Molecular Adsorbent Recirculating System (MARS) therapy on total plasma piperacillin concentrations in critically ill patients with acute liver failure or acute-on-chronic liver failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN:<\/jats:title>\n                    <jats:p>Retrospective, single-center observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTING:<\/jats:title>\n                    <jats:p>University ICU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS:<\/jats:title>\n                    <jats:p>Consecutive adult patients treated with MARS therapy and piperacillin-tazobactam between March 2023 and June 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>INTERVENTIONS:<\/jats:title>\n                    <jats:p>MARS therapy was delivered as 8-hour sessions for up to three consecutive days. Piperacillin-tazobactam was administered by continuous infusion following a loading dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n                    <jats:p>\n                      Venous blood samples were collected immediately before and after each MARS session. Total piperacillin concentrations were quantified using ultrahigh-performance liquid chromatography. The primary endpoint was the relative reduction in plasma piperacillin concentration induced by MARS therapy. Thirty patients (121 piperacillin measurements across 77 sessions) were analyzed. Seventy-three percent had cirrhosis (median Model for End-Stage Liver Disease Score 31 [23\u201338]). The mean relative reduction in piperacillin concentration per session was 34% (\u00b1 7.9%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.05). In univariable mixed-effects analysis, MARS session (\u03b2 \u201347.49\u2009mg\/L;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001) and creatinine clearance (\u03b2 \u20130.37\u2009mg\/L per mL\/min;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001) were associated with lower concentrations. In multivariable modeling, higher creatinine clearance was independently associated with greater intra-session piperacillin loss (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001), whereas higher bilirubin levels were associated with reduced drug loss (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.01). Overall, 31.6% of post-session concentrations were less than 80\u2009mg\/L, and 38% of patients had at least one concentration outside the predefined target range.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>MARS therapy was associated with a one-third reduction in total plasma piperacillin concentrations per session. These findings support systematic therapeutic drug monitoring and individualized antibiotic dose adjustment during MARS therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ccm.0000000000007235","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:01:14Z","timestamp":1781622074000},"page":"2361-2372","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Molecular Adsorbent Recirculating System Therapy on Piperacillin Concentration in Critically Ill Patients: An Observational Cohort Study"],"prefix":"10.1097","volume":"54","author":[{"given":"Cl\u00e9ment","family":"Monet","sequence":"first","affiliation":[{"name":"Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Montpellier, Cedex 5, France."},{"name":"Research Unit, PhyMedExp, INSERM U1046, CNRS UMR, Montpellier, Cedex 5, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Allegre","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Montpellier, Cedex 5, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Kozoriz","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Montpellier, Cedex 5, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanchon","family":"Herman","sequence":"additional","affiliation":[{"name":"Clinical Research and Epidemiology Unit, La Colombi\u00e8re University Hospital, Montpellier, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Lakbar","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Montpellier, Cedex 5, France."},{"name":"Research Unit, PhyMedExp, INSERM U1046, CNRS UMR, Montpellier, Cedex 5, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Prades","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Montpellier, Cedex 5, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Pensier","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Montpellier, Cedex 5, France."},{"name":"Research Unit, PhyMedExp, INSERM U1046, CNRS UMR, Montpellier, Cedex 5, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"De Jong","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Montpellier, Cedex 5, France."},{"name":"Research Unit, PhyMedExp, INSERM U1046, CNRS UMR, Montpellier, Cedex 5, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Molinari","sequence":"additional","affiliation":[{"name":"Research Unit, IDESP, INSERM, PreMEdical INRIA, University of Montpellier, CHU Montpellier, Montpellier, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7257-8069","authenticated-orcid":false,"given":"Samir","family":"Jaber","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Montpellier, Cedex 5, France."},{"name":"Research Unit, PhyMedExp, INSERM U1046, CNRS UMR, Montpellier, Cedex 5, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/gutjnl-2016-312670","article-title":"Acute-on-chronic liver failure: An update.","volume":"66","author":"Hernaez","year":"2017","journal-title":"Gut"},{"key":"R3-20260908","first-page":"667","article-title":"Bacterial infections in acute-on-chronic liver failure: Epidemiology, diagnosis, pathogenesis, and management.","volume":"12","author":"Xu","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/gutjnl-2017-314240","article-title":"Bacterial and fungal infections in acute-on-chronic liver failure: Prevalence, characteristics and impact on prognosis.","volume":"67","author":"Fern\u00e1ndez","year":"2018","journal-title":"Gut"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1056\/NEJMra1208937","article-title":"Acute liver failure.","volume":"369","author":"Bernal","year":"2013","journal-title":"N Engl J Med"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1478-3231.2010.02219.x","article-title":"Admission levels and early changes in serum interleukin-10 are predictive of poor outcome in acute liver failure and decompensated cirrhosis.","volume":"30","author":"Berry","year":"2010","journal-title":"Liver Int"},{"key":"R7-20260908","first-page":"143","article-title":"Management of liver failure in general intensive care unit.","volume":"39","author":"Paugam-Burtz","year":"2020","journal-title":"Anaesth Crit Care Pain Med"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.12923","article-title":"Prevalence of antimicrobial use in US acute care hospitals, May-September 2011.","volume":"312","author":"Magill","year":"2014","journal-title":"JAMA"},{"key":"R9-20260908","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017.","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"R10-20260908","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diagmicrobio.2005.12.009","article-title":"Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).","volume":"56","author":"Rhomberg","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R11-20260908","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR).","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"R12-20260908","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3109\/15563650.2011.624102","article-title":"Use of the Molecular Adsorbent Recirculating System (MARSTM) for the management of acute poisoning with or without liver failure.","volume":"49","author":"Wittebole","year":"2011","journal-title":"Clin Toxicol Phila Pa"},{"key":"R13-20260908","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1046\/j.1440-1746.17.s3.14.x","article-title":"Molecular Adsorbent Recirculating System: Albumin dialysis-based extracorporeal liver assist device.","volume":"17","author":"Kapoor","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R14-20260908","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s13054-022-04165-z","article-title":"Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS\u00ae in a single center.","volume":"26","author":"Monet","year":"2022","journal-title":"Crit Care"},{"key":"R15-20260908","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s00134-022-06802-1","article-title":"Artificial liver support in patients with liver failure: A modified DELPHI consensus of international experts.","volume":"48","author":"Saliba","year":"2022","journal-title":"Intensive Care Med"},{"key":"R16-20260908","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4161\/org.7.1.14069","article-title":"Extracorporeal liver support.","volume":"7","author":"Stange","year":"2011","journal-title":"Organogenesis"},{"key":"R17-20260908","first-page":"208","article-title":"Liver support devices.","volume":"14","author":"Phua","year":"2008","journal-title":"Curr Opin Crit Care"},{"issue":"Suppl 3","key":"R18-20260908","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1478-3231.2011.02589.x","article-title":"Albumin dialysis: Current practice and future options.","volume":"31","author":"Wauters","year":"2011","journal-title":"Liver Int"},{"key":"R19-20260908","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000232940","article-title":"Role of cytokines in the pathophysiology of acute-on-chronic liver failure.","volume":"28","author":"Liu","year":"2009","journal-title":"Blood Purif"},{"key":"R20-20260908","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/cc5922","article-title":"Bench-to-bedside review: Current evidence for extracorporeal albumin dialysis systems in liver failure.","volume":"11","author":"Karvellas","year":"2007","journal-title":"Crit Care"},{"issue":"Suppl 1","key":"R21-20260908","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1665-2681(19)31602-3","article-title":"Extracorporeal liver support-albumin dialysis with the Molecular Adsorbent Recirculating System (MARS).","volume":"10","author":"Mitzner","year":"2011","journal-title":"Ann Hepatol"},{"key":"R22-20260908","doi-asserted-by":"crossref","first-page":"e00583","DOI":"10.1128\/AAC.00583-19","article-title":"A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy.","volume":"63","author":"Pistolesi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20260908","first-page":"1839","article-title":"\u03b2-lactam dosing in critical patients: A narrative review of optimal efficacy and the prevention of resistance and toxicity.","volume":"11","author":"Pereira","year":"2022","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"R24-20260908","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/tid.12031","article-title":"Molecular Adsorbent Recirculating System (MARS(\u00ae)) removal of piperacillin\/tazobactam in a patient with acetaminophen-induced acute liver failure.","volume":"15","author":"Ruggero","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"R25-20260908","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/phar.1618","article-title":"Extracorporeal elimination of piperacillin\/tazobactam during Molecular Adsorbent Recirculating System therapy.","volume":"35","author":"Personett","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R26-20260908","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/phar.2462","article-title":"Molecular Adsorbent Recirculating System therapy with continuous renal replacement therapy enhanced clearance of piperacillin in a pediatric patient and led to failure to attain pharmacodynamic targets.","volume":"40","author":"Tang Girdwood","year":"2020","journal-title":"Pharmacotherapy"},{"key":"R27-20260908","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/aas.12041","article-title":"The effect of the Molecular Adsorbent Recirculating System on moxifloxacin and meropenem plasma levels.","volume":"57","author":"Roth","year":"2013","journal-title":"Acta Anaesthesiol Scand"},{"key":"R28-20260908","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3390\/ph14121214","article-title":"Quantification of 15 antibiotics widely used in the critical care unit with a LC-MS\/MS system: An easy method to perform a daily therapeutic drug monitoring.","volume":"14","author":"Feliu","year":"2021","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"R29-20260908","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new Simplified Acute Physiology Score (SAPS II) based on a European\/North American multicenter study.","volume":"270","author":"Le Gall","year":"1993","journal-title":"JAMA"},{"key":"R30-20260908","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/jama.286.14.1754","article-title":"Serial evaluation of the SOFA score to predict outcome in critically ill patients.","volume":"286","author":"Ferreira","year":"2001","journal-title":"JAMA"},{"key":"R31-20260908","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.4254\/wjh.v14.i12.2025","article-title":"CLIF-SOFA and CLIF-C scores for the prognostication of acute-on-chronic liver failure and acute decompensation of cirrhosis: A systematic review.","volume":"14","author":"Rashed","year":"2022","journal-title":"World J Hepatol"},{"key":"R32-20260908","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease.","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"R33-20260908","doi-asserted-by":"crossref","first-page":"e0063321","DOI":"10.1128\/Spectrum.00633-21","article-title":"Population pharmacokinetics and dosing optimization of piperacillin-tazobactam in critically ill patients on extracorporeal membrane oxygenation and the influence of concomitant renal replacement therapy. Ferran AA, \u00e9diteur.","volume":"9","author":"Hahn","year":"2021","journal-title":"Microbiol Spectr"},{"key":"R34-20260908","first-page":"531","article-title":"Predictive factors of piperacillin exposure and the impact on target attainment after continuous infusion administration to critically ill patients.","volume":"12","author":"Mart\u00ednez-Casanova","year":"2023","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"R35-20260908","first-page":"065","article-title":"A pharmacokinetic analysis of continuously infused piperacillin\/tazobactam in critically ill trauma patients.","volume":"4","author":"Silinskie","year":"2018","journal-title":"Trauma Cases Rev"},{"key":"R36-20260908","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1136\/ejhpharm-2018-001713","article-title":"Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: A prospective cohort study in critically ill patients.","volume":"27","author":"Schoenenberger-Arnaiz","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"R37-20260908","doi-asserted-by":"crossref","first-page":"ofad143","DOI":"10.1093\/ofid\/ofad143","article-title":"Early target attainment with continuous infusion meropenem and piperacillin\/tazobactam and utilization of therapeutic drug monitoring in critically ill patients: A retrospective cohort study from 2017 to 2020.","volume":"10","author":"Dr\u00e4ger","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R38-20260908","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jcrc.2019.04.013","article-title":"Early target attainment of continuous infusion piperacillin\/tazobactam and meropenem in critically ill patients: A prospective observational study.","volume":"52","author":"Dhaese","year":"2019","journal-title":"J Crit Care"},{"key":"R39-20260908","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000440973","article-title":"Adsorption of selected antibiotics to resins in extracorporeal blood purification.","volume":"41","author":"Harm","year":"2016","journal-title":"Blood Purif"},{"key":"R40-20260908","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R41-20260908","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: Defining antibiotic levels in intensive care unit patients: Are current-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R42-20260908","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1128\/AAC.00144-06","article-title":"\u03b2-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa.","volume":"50","author":"Gugel","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R44-20260908","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/cid\/ciaa224","article-title":"The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: Data from the multinational sampling antibiotics in renal replacement therapy study.","volume":"72","author":"Roberts","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R45-20260908","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijantimicag.2017.03.018","article-title":"Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.","volume":"50","author":"Roger","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R46-20260908","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jac\/dkab031","article-title":"Impact of extracorporeal membrane oxygenation (ECMO) support on piperacillin exposure in septic patients: A case-control study.","volume":"76","author":"Fill\u00e2tre","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R47-20260908","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2007.09.013","article-title":"A novel way to investigate the effects of plasma exchange on antibiotic levels: Use of microdialysis.","volume":"31","author":"Roberts","year":"2008","journal-title":"Int J Antimicrob Agents"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCM.0000000000007235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:01:45Z","timestamp":1788886905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CCM.0000000000007235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000007235","relation":{},"ISSN":["0090-3493","1530-0293"],"issn-type":[{"value":"0090-3493","type":"print"},{"value":"1530-0293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}